Add like
Add dislike
Add to saved papers

Dual-source dual-energy MDCT of pancreatic adenocarcinoma: initial observations with data generated at 80 kVp and at simulated weighted-average 120 kVp.

OBJECTIVE: The purpose of this study was to determine whether the conspicuity of malignant tumors of the pancreas at dual-source dual-energy CT is better with 80-kVp acquisition than with 120-kVp acquisition simulated with a weighted average.

MATERIALS AND METHODS: Fifteen patients with pancreatic adenocarcinoma underwent contrast-enhanced dual-source dual-energy CT. The abdominal diameter of all patients was 35 cm or less. Data were reconstructed as a weighted average of the 140- and 80-kVp acquisitions, simulating 120 kVp, and as a pure 80-kVp data set. A region-of-interest cursor was placed within the tumor and the adjacent normal parenchyma, and attenuation differences and contrast-to-noise ratios were calculated for pancreatic tumors at 80 kVp and with the weighted-average acquisition. The 80-kVp and weighted-average images were subjectively compared in terms of lesion conspicuity, image quality, and duct visualization. An exact Wilcoxon's matched pairs signed rank test was used to test whether differences in attenuation, contrast-to-noise ratio, and subjective assessment were greater at 80 kVp.

RESULTS: The mean difference in attenuation for each pancreatic tumor and adjacent portion of normal pancreas was 83.27+/-29.56 (SD) HU at 80 kVp and 49.40+/-23.00 HU at weighted-average 120 kVp. Adenocarcinoma attenuation differences were significantly greater at 80 kVp than at 120 kVp (p=0.00006). Contrast-to-noise ratio was significantly higher at 80 kVp than at 120 kVp (p=0.00147). Subjective analysis showed lesion conspicuity (p=0.001) and duct visualization (p=0.0156) were significantly better on the 80-kVp images.

CONCLUSION: At portal venous phase dual-source dual-energy CT, the conspicuity of malignant tumors of the pancreas is greater at 80 kVp than with weighted-average acquisition.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app